Location: | Norwich |
---|---|
Salary: | £37,999 per annum, with an annual increment up to £45,163 per annum |
Hours: | Full Time |
Contract Type: | Fixed-Term/Contract |
Placed On: | 9th October 2024 |
---|---|
Closes: | 8th November 2024 |
Job Ref: | RA2261 |
Salary on appointment will be £37,999 per annum, with an annual increment up to £45,163 per annum
An exciting opportunity exists for a Senior Research Associate to run the Molecular Diagnostic Laboratory at UEA to analyse prostate cancer patient’s urine and tissue samples for the PUR and DESNT poor prognosis expression markers. This is an independent role responsible for supervising all aspects of the diagnostic tests. Roles include supervising laboratory workers, operating and maintaining specialised equipment, setting up and maintaining an accurate and efficient pipeline for sample analysis that can be monitored at all points to high test-standards that meet laboratory accreditation criteria for analysis and ensure an efficient roll out of these tests to patients.
The PUR urine biomarker study is a validation study that is a continuation of our published PUR (Prostate Urine Risk) research (Connell et al., 2019 BJUInt) and is part of the ongoing process of making a clinically implementable test for prostate cancer which uses samples that can be provided by patients at home.
The DESNT tissue expression study is a continuation of our prostate cancer stratification using the DESNT poor prognosis biomarker (Luca et al., 2017, Eur Urol Focus). Not all prostate cancers are the same and subdividing cancer into better or poorer outcome cancers is key to personalised treatment pathways.
You will be responsible for organising and running individual research projects, linking to cancer-tissue expression studies within Cancer Genetics and to Clinical Research Trials throughout the UK and beyond. You will contribute to study design, trial performance, data analysis, preparation of grants and publications. Presenting results internally and at national and international meetings.
The position will require good experience in molecular biology and will continue the work built on our recently published research on the PUR and DESNT tests for aggressive prostate cancer.
The post requires someone with interpersonal skills, who is good at organising their time and has attention to detail. Skills in molecular biology techniques are essential.
This full-time post is available from 1 December 2024 on a fixed term basis for two years.
Further information on our great benefits package, including 44 days annual leave inclusive of Bank Holidays and additional University Customary days, can be found on our benefits page.
Closing date: 8 November 2024
The University holds an Athena Swan Silver Institutional Award in recognition of our advancement towards gender equality.
Type / Role:
Subject Area(s):
Location(s):